Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cerevel Therapeutics
Biotech
Phase 2 schizophrenia fails will cost AbbVie about $3.5B
Emraclidine, acquired in the $8.7B purchase of Cerevel Therapeutics, showed no difference compared to placebo in improving schizophrenia symptoms.
Darren Incorvaia
Jan 10, 2025 11:06am
AbbVie's Parkinson's prospect improves motor function in ph. 3
Dec 9, 2024 9:34am
AbbVie's $9B schizophrenia prospect flunks phase 2 trials
Nov 11, 2024 10:06am
AbbVie Parkinson's drug from $8.7B Cerevel buyout scores
Sep 26, 2024 10:45am
Bain unveils $3B fund for life science companies
Sep 10, 2024 11:20am
AbbVie axes Alzheimer's program amid 'evolving landscape'
Jul 25, 2024 10:49am